Y-mAbs Therapeutics, Inc. (YMAB)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ: YMAB). The investigation concerns whether Y-mAbs and certain of its officers and/or directors have violated federal securities laws.


On October 5, 2020, post-market, Y-mAbs issued a press release disclosing receipt of “a Refusal to File letter from the U.S. Food and Drug Administration (‘FDA’) regarding the Biologics License Application (‘BLA’) for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, which was submitted in August 2020.”  Y-mAbs advised investors that “[u]pon preliminary review, the FDA determined that certain parts of the Chemistry, Manufacturing and Control (‘CMC’) module and the Clinical module of the BLA require further detail.”  On this news, y-mAbs’s stock price fell $3.57 per share, or 8.56%, to close at $38.13 per share on October 6, 2020.


If you are aware of any facts relating to this investigation, or purchased Y-mAbs shares,  you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.